Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Down syndrome (DS) individuals develop several neuropathological hallmarks seen in Alzheimer's disease, including cognitive decline and the early loss of cholinergic markers in the basal forebrain. These deficits are replicated in the Ts65Dn mouse, which contains a partial trisomy of murine chromosome 16, the orthologous genetic segment to human chromosome 21. Oxidative stress levels are elevated early in DS, and may contribute to the neurodegeneration seen in these individuals. We evaluated oxidative stress in Ts65Dn mice, and assessed the efficacy of long-term antioxidant supplementation on memory and basal forebrain pathology. We report that oxidative stress was elevated in the adult Ts65Dn brain, and that supplementation with the antioxidant vitamin E effectively reduced these markers. Also, Ts65Dn mice receiving vitamin E exhibited improved performance on a spatial working memory task and showed an attenuation of cholinergic neuron pathology in the basal forebrain. This study provides evidence that vitamin E delays onset of cognitive and morphological abnormalities in a mouse model of DS, and may represent a safe and effective treatment early in the progression of DS neuropathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 1×
“1983), and thereby influence the processing of information necessary for attention and cognition in both animals and humans (Perry et al., 1977; Whitehouse et al., 1982).”
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 2×
“There have been many clinical trials attempting to establish whether antioxidant treatment is efficacious in neurodegenerative disease, including two large-scale interventional trials in AD (Petersen et al., 2005; Sano et al., 1997).”
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
A mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 4×
“These pathologies occur despite the absence of amyloid plaques in the Ts65Dn mouse (Reeves et al., 1995), though elevations in both APP (Seo and Isacson,2005) and β-amyloid (Hunter et al.”
InfluentialApoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro
Busciglio, J., & Yankner, B. A. (1995) · Nature · doi:10.1038/378776a0 · Cited by 741
Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543 · cited 4×
“, 2003), diminished nerve growth factor transport, and BFCN loss in the Ts65Dnmouse (Salehi et al., 2006).”
InfluentialSelf-citationOxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease
Lovell, M. A., & Markesbery, W. R. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm821 · Cited by 515
Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome
Holtzman, D. M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D. J., Daniels, S. E., Johnson, R. M., Chen, K., Sun, Y., Carlson, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13333 · Cited by 448
Cooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336 · cited 2×
“, 2000), followed by progressive neuronal loss starting at 10 months of age (Cooper et al., 2001; Hunter et al., 2004a,b; Seo and Isacson, 2005) as evidenced by others as well (Cooper et al.”
Association of vitamin E and C supplement use with cognitive function and dementia in elderly men
Masaki, K. H., Losonczy, K. G., Izmirlian, G., Foley, D. J., Ross, G. W., Petrovitch, H., Havlik, R., & White, L. R. (2000) · Neurology · doi:10.1212/wnl.54.6.1265 · Cited by 330
Tamagno, E., Parola, M., Bardini, P., Piccini, A., Borghi, R., Guglielmotto, M., Santoro, G., Davit, A., Danni, O., Smith, M. A., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02895.x · Cited by 324
Synaptic structural abnormalities in the Ts65Dn mouse model of down syndrome
Belichenko, P. V., Masliah, E., Kleschevnikov, A. M., Villar, A. J., Epstein, C. J., Salehi, A., & Mobley, W. C. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20337 · Cited by 297 · cited 1×
“Although cholinergic degeneration is recognized as an important biomarker for dysfunctional limbic system pathways, the hippocampus exhibits early morphologic and electrophysiologic pathology in the Ts65Dn mouse (Belichenko et al., 2004).”
Cataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., Carlson, E. J., Staufenbiel, M., & Nixon, R. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06788.2003 · Cited by 241 · cited 2×
“, 1992) accumulates in vesicles known to build up in this model (Cataldo et al., 2003).”
Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome
Siarey, R. J., Stoll, J., Rapoport, S. I., & Galdzicki, Z. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00157-3 · Cited by 222 · cited 1×
“Vitamin E may be acting to facilitate learning and memory by a similar mechanism here, as the Ts65Dn mouse has been found to exhibit significant LTP impairments (Siarey et al., 1997).”
High-dose antioxidant supplements and cognitive function in community-dwelling elderly women
Grodstein, F., Chen, J., & Willett, W. C. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.4.975 · Cited by 214 · cited 1×
“, 1997), longitudinal studies have shown vitamin E to reduce cognitive loss and dementia (Grodstein et al., 2003; Masaki et al., 2000).”
Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of down syndrome.
Insausti, A. M., Megı́as, M., Crespo, D., Cruz-Orive, L. M., Dierssen, M., Vallina, T. F., Insausti, R., & Flórez, J. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00641-7 · Cited by 149
Bayer, T. A., & Wirths, O. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00372.x · Cited by 60 · cited 1×
“There is substantial evidence that monomers and oligomers of β-amyloid, derived from β-secretase activity, are toxic in the brain, disrupting cell signaling, causing synapse degeneration, and in some cases leading to neuronal death (Bayer and Wirths, 2008).”
Cited by
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Damaging effects of a high-fat diet to the brain and cognition: A review of proposed mechanisms
Freeman, L. R., Haley-Zitlin, V., Rosenberger, D. S., & Granholm, A.-C. (2014) · Nutritional Neuroscience · doi:10.1179/1476830513y.0000000092 · Cited by 324
Self-citationCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Vitamin E Inadequacy in Humans: Causes and Consequences
Traber, M. G. (2014) · Advances in Nutrition · doi:10.3945/an.114.006254 · Cited by 279
Metadata
- Authors
- Lockrow, J., Prakasam, A., Huang, P., Bimonte-Nelson, H., Sambamurti, K., & Granholm, A.-C.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 216
- Issue
- 2
- Pages
- 278-289
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2035923900
- Cited by
- 123
- References
- 20
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.